RFK Jr. says peptides are like supplements. They're not.

What did @mosheh actually say?

The video presents RFK Jr.'s congressional testimony arguing that peptides should be treated like supplements, not prescription drugs. His core claim: the Biden administration "improperly moved them to category three without any evidence of safety" and that this decision has since been reversed. He's saying FDA overstepped, courts have sided against it, and the science never justified restricting these compounds in the first place.

This is a regulatory argument dressed up as a science argument, and those are two different things. You can believe FDA acted improperly on procedural grounds while still acknowledging that many of these peptides lack robust human clinical trials. RFK Jr. conflates the two throughout, which is worth unpacking carefully.

Does the science back this up?

On the regulatory history, he's mostly accurate. On the safety science, the picture is far more complicated than his framing suggests.

The FDA's 2023 decision to place several peptides, including BPC-157, on the Category 2 and Category 3 lists under the 503A and 503B compounding frameworks, was contested. Critics, including compounding pharmacy trade groups, argued the agency did not provide adequate scientific justification for reclassifying compounds that had circulated in clinical settings for years. A federal court challenge in 2024 found procedural problems with how FDA conducted the rulemaking process, which is the "upheld again and again" RFK Jr. references.

But here's the gap: a procedural win doesn't mean these peptides have established safety profiles. BPC-157, perhaps the most popular compounded peptide, has promising animal data (Chang et al., 2011, Journal of Physiology-Paris) but no completed Phase III human trials. The absence of a proven safety problem is not the same as a proven safety record, and conflating those two ideas is one of the most common errors in this space.

What did they get wrong (or right)?

RFK Jr. gets the regulatory critique largely right. The Biden-era FDA rulemaking on peptides was criticized even by researchers and clinicians who were not reflexively anti-regulation. The process lacked the kind of formal evidence review that typically accompanies major reclassification decisions, and courts agreed there were procedural deficiencies. Credit where it's due.

Where he goes wrong is the supplement analogy. Supplements are regulated under DSHEA (1994), a framework widely criticized by pharmacologists for setting an extremely low safety bar. Saying "peptides are like supplements" is not a defense of peptide safety; it's actually a concession that the safety evidence threshold is minimal. Many peptides in clinical use, like CJC-1295, ipamorelin, and TB-500, are pharmacologically active compounds that alter hormone signaling. Comparing them to vitamin D or fish oil is scientifically inaccurate. Peptides that modulate growth hormone release (Sigalos and Pastuszak, 2018, Sexual Medicine Reviews) carry real physiological effects that supplements generally do not.

He also claims there was "no science" indicating a safety concern. That's an overstatement. There is limited science in either direction for many of these compounds in humans, which is a different problem entirely.

What should you actually know?

If you're considering peptide therapy, the regulatory fight happening in Washington matters, but it doesn't answer the question you actually need answered: what do we know about long-term safety in humans?

For most compounded peptides currently popular in telehealth, the honest answer is: not much. BPC-157 has compelling rodent data for tissue repair and gut healing, but human trial data is sparse and largely unpublished (Seiwerth et al., 2018, Current Pharmaceutical Design). GHK-Cu has interesting in vitro work on wound healing and collagen synthesis (Pickart et al., 2015, Journal of Aging Research), but "interesting lab results" and "proven clinical benefit" are not the same category.

The regulatory rollback RFK Jr. is describing may open access to these compounds through compounding pharmacies, but access is not the same as evidence. A regulated telehealth platform should be doing individualized clinical evaluation before any peptide is considered, not pointing to Washington as a reason to skip that step. The FDA fight is about who gets to make these decisions, not about whether the decisions have been made correctly by science.

Bottom line: regulatory win, science still unsettled

RFK Jr.'s argument that FDA overstepped procedurally has real legal backing. His argument that peptides are safe because there's no proof they're dangerous is a logical fallacy, not a scientific conclusion. The supplement comparison is a political frame, not a pharmacological one. These are active compounds, and the fact that compounding pharmacies may now be permitted to manufacture them does not mean the human safety and efficacy literature has caught up. It hasn't, for most of them.